You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 196031 - 196040 of 205043 results
  1. First in Human Phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy

    SBC: ONCOC4, INC.            Topic: 102

    Summary A major paradigm in cancer immunotherapy is to use checkpoint inhibitors to break regulatory mechanisms that guard the host against autoimmune diseases. CTLA-4-targeting immunotherapy was the first example to establish this paradigm. However, the clinically tested anti-CTLA-4 antibodies exhibit suboptimal efficacy but high toxicity. Our preclinical study demonstrate that this outcome is pr ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  2. Evaluating the Usability, Efficacy and Commercial Utility of a Digital Platform to Deliver Comprehensive Treatment for Opioid Use Disorder

    SBC: Boulder Care, Inc.            Topic: NIDA

    7. PROJECT SUMMARY Opioid use disorder (OUD) is a problem of national concern. Medication-based treatment (MT) reduces opioid use, associated risk behaviors and death. Despite evidence supporting MT with buprenorphine, in more than ½ of US counties (mainly rural), there are no prescribers. Patients travel long distances, join waitlists, or go without MT. Other barriers to care include lack of tra ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  3. Inhibition of NF1 Protein Degradation as a Treatment for NF1 Haploinsufficiency

    SBC: INFIXION BIOSCIENCE INC            Topic: NINDS

    PROJECT ABSTRACT. Haploinsufficiency plays a crucial role in Neurofibromatosis (NF1), an autosomal dominant genetic disorder impacting over 120,000 Americans. Current therapeutic approaches target downstream components of NF1 signaling, for example MEK inhibition in tumors, thus failing to address the broad range of signaling and symptoms associated with NF1 mutations. Given that NF1 is characteri ...

    SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  4. Treg-depleting immunotherapy

    SBC: SONOVAL LLC            Topic: 102

    Abstract Sonoval is expanding its successful biologic drug platform technology to develop second generation versions of the cancer therapeutic Ontak, with the potential to advance the field of regulatory T cells (Tregs)-depleting immunotherapy through a mechanism previously unique to Ontak alone. Sonova;’s therapeutics will target Tregs for treatment of major solid tumors, which afflict rt50,000 ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a Universal Immunotherapeutic for Influenza Viruses

    SBC: Integrated Biotherapeutics, Inc.            Topic: NIAID

    Project Summary Influenza virus (INFV) results in global seasonal and pandemic outbreaks estimated to cause severe illness in 3 to 5 million people annually resulting in significant morbidity and up to 650,000 deaths. The influenza burden also results in substantial economic loss. The goal of this program is to develop a therapeutic antibody offering effective treatment with broad heterosubtypic s ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  6. RAE (Realize, Analyze, Engage)- A Digital Biomarker Based Detection and Intervention System for Stress and Craving During Recovery from Substance Abuse Disorders

    SBC: CONTINUEYOU, LLC            Topic: NIDA

    PROJECT SUMMARY The research project outlined in this SBIR submission will develop the Realize, Analyze, Engage (RAE) platform into a tool to promote sustained recovery in individuals receiving treatment for substance use disorder. In this proposal, the investigators intend to deploy the RAE system- consisting of a wearable sensor, a smartphone app, and a clinical portal- to provide individuals in ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  7. Novel therapy for Fragile X syndrome

    SBC: Epigen Biosciences, Inc.            Topic: 101

    PROJECT SUMMARY Fragile X syndrome (FXS) is the most common inheritable form of cognitive impairment and the leading known genetic cause of autism. FXS is caused by the loss of expression of the fragile X mental retardation protein (FMRP). A major challenge for FXS research is to develop treatment strategies that improve the intellectual capabilities of patients. Dysregulated protein synthesis is ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  8. Novel Dopaminergic Stimulant Prodrug for the Treatment of Apathy in AD

    SBC: Praxis Biosciences            Topic: NIA

    PROJECT SUMMARY The goal of this project is to develop PRX-P4-003 as a safer “first-in-class” FDA-approved therapy for apathy in Alzheimer’s Disease (AD). Apathy is one of the most common neurobehavioral symptoms of AD (rt70% of patients) and is defined as loss of initiative and interest in daily activity in the absence of depression or other mood changes. These symptoms are associated with ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  9. SBIR Phase I:Artificial intelligence platform for secure, collaborative learning across medical institutions

    SBC: SOAR ANALYTICS LLC            Topic: DH

    The broader impact / commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to develop a collaborative-learning platform that generates accurate population health models from secure access to patient records.The proposed system will overcome privacy concerns to enable AI methods to securely access hundreds of millions of patient records from multiple institutions ...

    SBIR Phase I 2022 National Science Foundation
  10. SBIR Phase I:Developing NLP-based Platform Technology for Phage-Host Interaction Predictions

    SBC: Uniphage, Inc.            Topic: BT

    The broader impact of this Small Business Innovation Research (SBIR) Phase I project is to improve agricultural operations with respect to infection.Antibiotic resistance in crops is increasing. One of the most promising alternatives to antibiotics is bacteriophages, also known as phages. Phages are safe bacterial viruses already used on a small commercial scale in the United States. One major bot ...

    SBIR Phase I 2022 National Science Foundation
US Flag An Official Website of the United States Government